Optimizing Antiplatelet Therapy in the ACS Patient: Limitations of Current Antiplatelet Therapy in ACS and PCI and Potential Solutions

Faculty

Stephen D. Wiviott, MD
Assistant Professor of Medicine
Harvard Medical School
Investigator, TIMI Study Group
Associate Physician, Cardiovascular Division
Brigham and Women's Hospital

Needs Statement

This presentation aims to focus on current strategies to optimize oral antiplatelet agents in the treatment of ACS and PCI. Topics addressed include current limitations with clopidogrel, variability in response to clopidogrel and the clinical outcomes associated with poor response, and strategies to reduce variability. Finally, a comparison of the biologic response of prasugrel and clopidogrel is presented, along with an analysis of variability in response between these two agents.

Target Audience

This activity is intended for interventional cardiologists, general cardiologists, internists and other healthcare professionals involved in the management of patients experiencing an acute coronary syndrome.

Objectives

1. Describe current limitations and variability in patient response to clopidogrel and;
2. Identify key differences in the biologic response of prasugrel when compared with clopidogrel.

Accreditation

Medicine
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit actually spent in the educational activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Faculty Disclosure

Dr. Wiviott has received research support from Eli Lilly and Co. and Daiichi-Sankyo, Inc.; serves on the speakers bureau for Pfizer; and serves as a consultant to Amgen, Arena Pharmaceuticals, Biogen-Idec, Forrest Laboratories, Molecular Insight, Sanofi-Aventis, Abbott Pharmaceuticals, NicOx, Inotek Pharmaceuticals.

Activity Sponsorship